Treatment News : Norvir-Boosted Reyataz Comparable in HIV-Positive Women Versus Men - by Tim Horn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » July 2011

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

July 25, 2011

Norvir-Boosted Reyataz Comparable in HIV-Positive Women Versus Men

by Tim Horn

Antiretroviral (ARV) drug regimens containing Norvir (ritonavir)–boosted Reyataz (atazanavir) appear to work just as well for women, compared with men, in the “real world,” according to an analysis of three databases reported Monday, July 18, at the 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention in Rome.

According to the report by María Jesús Jiménez-Expósito, MD, of Bristol-Myers Squibb and her colleagues, the evaluation of nearly 1,300 treatment-experienced women and men didn’t find any significant differences in rates of virologic failure while using Norvir-boosted Reyataz-based regimens during an average three-year follow-up period. The researchers did note that treatment discontinuation rates were higher among women, but not for efficacy reasons.

Despite the facts that nearly 16 million women are living with HIV worldwide and the disease has become the leading cause of death among women of reproductive age globally, data on the efficacy and safety of ARV therapy in women remain limited. The primary reason for this is that women have historically been under-represented in clinical trials.

To shed some light on the efficacy and safety of a popular protease inhibitor-based option, particularly in industrialized nations, Jiménez-Expósito’s group reviewed data from three European databases: DatAids in France, KompNet in Germany and InfCare in Sweden. The analysis included 336 HIV treatment-experienced women and 958 treatment-experienced men who began a Norvir-boosted Reyataz regimen between October 2004 and March 2007. The women were an average of four years younger—40 versus 44, a statistically significant difference—but had been on antiretroviral therapy for the same length of time as the men in the evaluation: about five years. 

The results revealed no gender-based differences regarding the amount of time before reaching virologic failure, defined as two consecutive viral loads above 50 copies or one viral load above 50 copies followed by discontinuation. After three years of follow-up, durable efficacy was confirmed in 59 percent of the women and 63 percent of the men. This difference was not statistically significant, meaning that it was small enough to have occurred by chance.

Women were more likely to discontinue treatment in the study, a finding that mirrors those of other studies. Whereas 40 percent of the men stopped their Norvir-boosted Reyataz at some point during the follow-up period, 52 percent of the women discontinued treatment. Some moderate differences in the reasons for treatment discontinuation were reported, including adverse events (14 versus 10 percent), as well as pregnancy. Virologic failure, however, was no more likely to contribute to treatment discontinuation among the women compared with the men.

Generally speaking, however, adverse events were comparable. Among women, diarrhea was reported in 2 percent, nausea in less than 1 percent, yellowing of the skin and eyes (jaundice) in less than 1 percent, lipodystrophy in 5 percent and bone density abnormalities in less than 1 percent of the cases.

Norvir-boosted Reyataz, the researchers noted, “is an effective and well tolerated therapeutic option for treatment-experienced female and male patients with HIV infection.” This regimen, they add, “demonstrated durable virologic suppression irrespective of gender [and] resulted in a low rate of discontinuation over five years, although as previously reported, differences in gender were observed.” 

Search: Reyataz, atazanavir, women, efficacy, side effects, tolerability, discontinuation, men, Jimenez-Exposito, IAS, Rome, Bristol-Myers Squibb, BMS


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    Drew949
    South Orange County
    California


    Newhopenate
    New Hope
    Pennsylvania


    hollywoodvers1
    Los Angeles
    California


    humboman
    Baltimore
    Maryland
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.